Symbicort COPD approval (correction)
AstraZeneca's Symbicort 160/4.5 mcg is now approved for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including bronchitis and emphysema, with twice-daily inhalations, like GlaxoSmithKline's Advair 250/50 mcg. The original version of this story incorrectly reported Symbicort's indication and Advair's dosing (1"The Pink Sheet," March 9, 2009, p. 23). Also, AstraZeneca clarified that it will not promote Symbicort based on its risk profile and offered pricing data that differ from the estimates offered by a Decision Resources analyst in the story - the wholesale acquisition cost of Symbicort is listed as $5.87/day while the WAC for Advair is $6.35/day
You may also be interested in...
Symbicort's rapid onset of action and lack of pneumonia signal could be competitive advantages as the drug enters the market with its newly approved use for chonic obstructive pulmonary disease
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.